Viking Therapeutics, Inc. VKTX
Viking Therapeutics, Inc. (Nasdaq: VKTX) is a cardio-renal-metabolic drug developer. Its lead program, VK2735 (subcutaneous; VANQUISH-1 and VANQUISH-2), is in Phase 3 for Obesity. Its next catalyst on record is VK2735 oral: Initiate Phase 3 oral dosing studies (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VK2735 oral — Initiate Phase 3 oral dosing studies (Q4 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VK2735 subcutaneous (VANQUISH-1/-2) | Obesity | protein/peptide | Phase 3 |
| VK2735 oral tablet | Obesity | protein/peptide | Phase 2 |
| VK2809 (TRb agonist) | NASH/MASH | small molecule | Phase 2 |
| VK5211 (SARM) | Muscle loss after hip fracture | small molecule | Phase 2 |
| VK2735 maintenance dosing study | Obesity (weight maintenance) | protein/peptide | Phase 1 |
| VK3019 (amylin agonist) | Obesity | protein/peptide | Phase 1 |
| VK0214 (TRb agonist) | X-linked adrenoleukodystrophy | small molecule | Phase 1 |
Recent results and decisions
- Sep 25, 2026n/a Viking Therapeutics issued $225 million aggregate principal amount of 2.00% Convertible Senior Notes due 2032.
Viking Therapeutics, Inc., a Delaware corporation (the "Company"), proposes to issue and sell to the several underwriters named in Schedule I hereto (the "Underwriters"), for whom Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as representatives (the "Representatives"), $225,000,
Filing - Sep 22, 2026positive Maintenance study topline: every-other-week dosing maintained up to 97% of weight loss and monthly up to 90% vs 61% for placebo (p<0.0001); weekly 17.5 mg gave 22% placebo-adjusted weight loss at week 33 with no plateau; GI AEs similar to placebo.
Subjects randomized to every-other-week dosing regimens maintained up to 97% of mean weight loss achieved in the weekly induction period.
Filing - Apr 29, 2026completed enrollment VANQUISH-2 Phase 3 completed enrollment in 1Q26 (~1,000 patients); VANQUISH-1 and -2 both fully enrolled.
During the first quarter of 2026, the company announced completion of enrollment in the VANQUISH-2 study. This study enrolled approximately 1,000 patients.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.